查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1379979

mRNA 平台市场 - 2018-2028 年全球产业规模、份额、趋势、机会和预测，按适应症、可用性、mRNA 类型、最终用户、地区和竞争细分

mRNA Platform Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented by Indication, by Usability, by mRNA Type, by End User, by region, and Competition
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

预计全球 mRNA 平台市场在预测期内将出现令人印象深刻的成长。 mRNA（信使RNA）平台是生物技术和医学领域的尖端技术，它利用合成RNA分子向细胞传递遗传讯息和指令，使它们能够产生特定的蛋白质。这项技术获得了极大的关注和成功，特别是在疫苗开发和各种疾病的治疗方面。 mRNA 是一种遗传物质，通常将 DNA（遗传密码）的指令传递给细胞的蛋白质製造机器（核醣体）。它充当基因指令的临时副本。在 mRNA 平台中，合成或修饰的 mRNA 分子被设计为携带用于生产特定蛋白质的特定遗传指令。科学家可以设计和合成具有精确遗传讯息的mRNA序列。这些资讯可以客製化用于各种目的，例如生产治疗性蛋白质或指示免疫系统产生免疫反应。在疫苗开发中，mRNA 平台用于创建 mRNA 疫苗。这些疫苗含有编码部分目标病原体的 mRNA 分子，例如病毒蛋白或独特抗原。

主要市场驱动因素

技术进步

脂质奈米颗粒 (LNP) 递送系统对于有效地将 mRNA 递送至细胞至关重要。 LNP 设计和配方的进步提高了 mRNA 疫苗和疗法的稳定性、传递和功效。这些进步对 COVID-19 mRNA 疫苗的成功发挥了关键作用。研究人员开发了经过修饰的 mRNA 序列，其稳定性增强，免疫原性降低。这延长了 mRNA 疫苗的保质期，使其更适合分发和储存。密码子优化涉及修改遗传密码以改善蛋白质表现。研究人员一直在微调密码子的使用以增强蛋白质的产生，这对于治疗应用尤其重要。 CRISPR-Cas9 等合成生物学技术的进步促进了 mRNA 序列的精确编辑和操作。这项技术为基于 mRNA 的遗传性疾病疗法开闢了新的可能性。可扩展且具有成本效益的製造流程已被开发出来，以满足对基于 mRNA 的疫苗和疗法的高需求。这些製造业的改进使得在突发公共卫生事件期间能够快速生产。研究人员在提高 mRNA 疫苗在不同温度范围内的稳定性、减少超低温储存和分发的需求方面取得了进展。新一代定序 (NGS) 使研究人员能够快速、准确地分析 mRNA 序列，从而有助于设计针对特定标靶的基于 mRNA 的疗法。

将帽子类似物添加到 mRNA 序列的开头以模拟天然 mRNA。这提高了合成 mRNA 的翻译效率并增加了其与内源性 mRNA 的相似性。用于 mRNA 生产的无细胞系统已经开发出来，可以更有效、更大规模地合成 mRNA 分子，用于研究和治疗目的。 mRNA 技术的进步促进了个人化医疗方法的发展，其中治疗方法是根据个人的基因图谱量身定制的。佐剂是一种添加到疫苗中以增强免疫反应的物质。研究重点是开发专门为基于 mRNA 的疫苗设计的新型佐剂。细胞内递送方法的创新，例如电穿孔和微针贴片，提高了 mRNA 进入目标细胞的效率。对 mRNA 配方和稳定性的广泛研究提高了在各种条件下储存和运输 mRNA 疫苗和疗法的能力。这一因素将有助于全球 mRNA 平台市场的发展。

新兴应用

最有前景的新兴应用之一是癌症免疫疗法。研究人员正在开发基于 mRNA 的癌症疫苗和疗法，以刺激患者的免疫系统瞄准并摧毁癌细胞。这种方法为各种类型的癌症提供了个人化且可能更有效的治疗方法。虽然mRNA 疫苗已经证明了其针对COVID-19 等传染病的有效性，但正在进行的研究旨在开发针对其他传染病的基于mRNA 的疫苗，例如流感、爱滋病毒、寨卡病毒和呼吸道合胞病毒(RSV)。 mRNA 技术的适应性使其非常适合应对新出现的病原体。 mRNA 技术正在探索用于治疗由特定突变引起的罕见遗传性疾病。透过提供修饰的 mRNA 来纠正遗传缺陷，研究人员旨在为患有囊性纤维化和某些遗传性代谢紊乱等疾病的患者提供有针对性的个人化治疗。 mRNA技术透过引导干细胞分化为特定细胞类型以进行组织修復和替换，在再生医学中具有潜在应用。这对于治疗退化性疾病和损伤特别有价值。 mRNA 可用于提供 CRISPR-Cas9 等基因编辑工具来针对和修改特定基因。这项技术有望治疗遗传疾病和纠正基因突变。研究人员正在探索 mRNA 来取代或补充遗传性或后天性蛋白质缺陷患者的缺陷蛋白质。这种方法可用于治疗血友病和某些酵素缺乏症等疾病。

mRNA 技术正在研究用于开发自体免疫疾病的疗法。透过调节免疫反应，基于 mRNA 的治疗可能有助于调节和控制自体免疫疾病。 mRNA 疫苗可以定制，以提供针对过敏的过敏原特异性免疫疗法。这种方法提供了更精确、更有效的过敏治疗的潜力。根据个别基因图谱客製化基于 mRNA 的疗法的能力是个人化医疗的重要驱动力。根据患者独特的基因组成客製化治疗可以改善治疗结果。除了医疗保健之外，mRNA 技术还应用于生物技术，包括重组蛋白和酵素的生产。它还具有在农业和工业生物技术等其他领域的应用潜力。这项因素将加快全球 mRNA 平台市场的需求。

流行病应对和疫苗的成长

mRNA 技术促进了 COVID-19 疫苗的快速开发。在非常短的时间内，Pfizer-BioNTech 和 Moderna 等公司开发、测试了基于 mRNA 的 COVID-19 疫苗，并获得了紧急使用授权。这种发展速度对于控制疫情至关重要。 mRNA 疫苗已表现出针对 COVID-19 的高水平功效，有助于其快速采用和广泛使用。这些疫苗在预防严重疾病和传播方面的有效性一直是需求的强劲推动力。 mRNA技术非常适合适应新的病毒变种。 mRNA 的灵活性允许快速修改候选疫苗，以应对新出现的病毒变种，从而解决面对病毒突变时疫苗有效性的担忧。 mRNA 疫苗的可扩展性和快速生产能力支持了全球疫苗接种工作。各国政府、国际组织和医疗保健系统都在寻求 mRNA 疫苗来保护其人口，推动了增加产量的需求。

这次大流行凸显了为新出现的传染病做好准备的重要性。世界各国政府和组织已经认识到 mRNA 技术在快速应对未来流行病的潜力，并投资建设基础设施和能力。基于 mRNA 的 COVID-19 疫苗的成功吸引了公共和私营部门的大量投资和资金。这项资金支持加速了研发工作并扩大了 mRNA 平台的应用。包括美国食品药物管理局 (FDA) 和欧洲药品管理局 (EMA) 在内的监管机构与 mRNA 技术开发商密切合作，以加速突发公共卫生事件期间的监管审批流程。 mRNA COVID-19 疫苗的有效性和安全性增强了公众对该技术的信心。因此，人们对基于 mRNA 的疫苗和疗法的接受度有所提高。 mRNA疫苗的成功刺激了该领域的进一步研究和开发。研究人员和公司正在探索 mRNA 技术在广泛应用中的潜力，包括其他传染病的疫苗和疗法。全球应对这场流行病需要各国、製药公司和研究机构之间的合作。此次合作加速了 mRNA 技术知识和专业知识的分享。这一因素将加速全球 mRNA 平台市场的需求。

主要市场挑战

疫苗犹豫和错误讯息

疫苗犹豫是指不愿意或拒绝接种疫苗，可能会减慢 mRNA 疫苗的采用。这可能会阻碍群体免疫和控制传染病传播的努力。错误讯息通常透过社群媒体和其他管道传播，可能导致人们对 mRNA 疫苗产生误解和错误信念。这可能包括对疫苗安全性、有效性和长期影响的担忧。错误讯息可能会削弱公众对疫苗的信心并阻止个人接种疫苗。由于犹豫和错误讯息而导致的疫苗覆盖率降低可能会导致可预防疾病的持续爆发，包括潜在致命的传染病，如 COVID-19。这些疫情可能会对医疗保健系统造成压力，导致发病率和死亡率增加，并产生经济和社会后果。对疫苗的高度犹豫可能会阻碍群体免疫的努力，而群体免疫对于保护因医疗原因无法接种疫苗的弱势群体至关重要。群体免疫对于控制传染病在社区内的传播至关重要。错误讯息和犹豫不决可能会扰乱疫苗接种活动，并导致疫苗接种率降低，特别是在流行病等突发公共卫生事件期间。普遍的疫苗犹豫和疫苗错误讯息的传播可能会削弱公众对公共卫生机构、医疗保健提供者和政府建议的信任。这种信任的侵蚀可能会延伸到其他公共卫生措施，使实施有效的疾病控制策略更具挑战性。

变体和适应性

许多传染性病原体，特别是病毒，可能会发生基因突变，导致新变种或病毒株的出现。这些变体可能具有不同的特性，包括增加的传播性和免疫力。变异可能导致更严重的疾病或降低疫苗有效性，对公共卫生构成威胁。疫苗（包括 mRNA 疫苗）的有效性可能因不同变异而异。有些变体可能部分逃避现有疫苗诱发的免疫反应。这挑战了疫苗针对不断进化的病原体提供广泛而持久的保护的能力。为了维持疫苗的有效性，研究人员和製造商需要快速调整 mRNA 疫苗以应对新出现的变异。这可能涉及修改 mRNA 序列以编码新变异体的抗原。在大流行和爆发期间，快速适应对于确保疫苗保持有效至关重要。监管机构可能需要为变异疫苗提供简化的审批流程，以加快其在公共卫生紧急情况下的可用性。开发变体特异性疫苗并获得监管部门的批准可能会占用大量资源且耗时。调整 mRNA 疫苗以应对新变种可能需要调整製造流程。扩大生产以满足全球对更新疫苗的需求可能具有挑战性。

主要市场趋势

个人化医疗

基因组学和基因测试的进步使得快速且经济地分析个体遗传资讯变得越来越可行。这种基因分析使医疗保健提供者能够识别可能影响疾病易感性和治疗反应的基因变异。 mRNA 技术能够开发可根据患者基因图谱量身定制的标靶疗法。透过设计 mRNA 序列来解决特定的遗传变异或疾病标记，研究人员可以创建个人化的治疗方法。在癌症方面，个人化医疗是一个值得注意的应用。研究人员正在探索基于 mRNA 的癌症疫苗和针对个人化肿瘤抗原的疗法。这些疗法旨在利用患者的免疫系统来专门瞄准并摧毁癌细胞。个人化 mRNA 疗法正在开发中，以解决由特定突变引起的罕见遗传疾病。透过客製化 mRNA 序列来纠正或补偿这些突变，研究人员正在努力提供个人化治疗。 mRNA 疫苗可以定制，以提供针对过敏的过敏原特异性免疫疗法。这种方法有可能针对每位患者的过敏原进行更精确、更有效的过敏治疗。 mRNA 技术可以透过分析基因表现的变化来监测患者对治疗的反应。这些资讯可用于调整和个人化治疗计划。将药物基因组资料与基于 mRNA 的疗法相结合，有助于确定最适合个别患者的药物和剂量，减少不良反应并优化治疗结果。

细分市场洞察

适应症见解

2022 年，全球 mRNA 平台市场最大份额由自体免疫疾病领域占据，预计未来几年将继续扩大。由于自体免疫疾病的复杂性和人们对自体免疫疾病的本质了解甚少，因此自体免疫疾病是一项重大的医学挑战。许多自体免疫疾病的治疗选择有限，而 mRNA 技术有望开发创新疗法，以满足该领域未满足的医疗需求。 mRNA技术可用于调节免疫系统，使其成为治疗自体免疫疾病的一种有吸引力的方法。透过设计针对特定免疫反应的 mRNA 序列，研究人员可以潜在地抑製或调节免疫系统在自体免疫条件下的有害活动。自体免疫疾病患者的表现和治疗反应通常各不相同。基于 mRNA 的疗法可以针对特定的自身免疫途径或抗原进行定制，从而实现个人化的治疗方法。

可用性见解

2022 年，治疗性疫苗领域占据全球 mRNA 平台市场最大份额，预计未来几年将继续扩大。 COVID-19 大流行对 mRNA 平台市场产生了重大影响。 mRNA 技术的出现是一种高效、快速的反应，可用于开发针对 SARS-CoV-2 病毒的疫苗。基于 mRNA 的 COVID-19 疫苗（例如辉瑞 BioNTech 和 Moderna 开发的疫苗）的成功引起了对该领域的巨大兴趣和投资。 mRNA技术已在开发针对传染病以外的各种疾病的治疗性疫苗方面展示了其多功能性。这包括癌症疫苗（基于 mRNA 的疗法旨在刺激免疫系统瞄准并摧毁癌细胞），以及针对流感、寨卡病毒和爱滋病毒等其他疾病的疫苗。 mRNA疫苗和治疗性疫苗的开发速度比传统疫苗平台更快。这种速度对于应对新出现的传染病和快速进化的病原体尤其有价值。

mRNA 型见解

2022 年，全球 mRNA 平台市场最大份额由自放大 mRNA 细分市场占据，预计未来几年将持续扩大。与传统 mRNA 相比，自扩增 mRNA (saRNA) 技术旨在产生更高水平的蛋白质表现。这种增强的蛋白质生产能力可以使 saRNA 对于疫苗开发和针对需要强大免疫反应的疾病的疗法特别有吸引力。自我扩增 mRNA 可以被设计为携带多种抗原或治疗蛋白质的遗传讯息。这种多功能性使其成为开发各种疾病（包括传染病和癌症）的疫苗和疗法的宝贵工具。用于传递自放大 mRNA 的先进脂质奈米粒子 (LNP) 的开发提高了基于 saRNA 的疫苗和疗法的稳定性和传递效率，进一步扩大了其市场份额。

最终使用者见解

2022 年，全球 mRNA 平台市场最大份额由製药公司部门在预测期内占据，预计未来几年将继续扩大。製药公司在药物发现和开发领域进行广泛的研究和开发 (R&D) 有着悠久的历史。他们拥有推进基于 mRNA 的疗法和疫苗所需的科学专业知识、基础设施和财政资源。 mRNA 技术在开发针对多种疾病的疫苗和疗法方面显示出巨大的前景，包括传染病、癌症和罕见的遗传性疾病。製药公司拥有将这些产品从研究阶段带到临床试验并最终商业化的经验和能力。进行临床试验是药物开发的关键部分。製药公司有能力进行大规模临床试验，这对于获得监管部门的批准并证明基于 mRNA 的产品的安全性和有效性是必要的。

区域洞察

2022年，北美地区将主导全球mRNA平台市场。北美是一些全球最大、最有影响力的生物技术和製药公司的所在地，其中许多公司在mRNA技术上投入了大量资金。辉瑞 (Pfizer)、Moderna 和 BioNTech 等公司在基于 mRNA 的 COVID-19 疫苗的开发和商业化中发挥了关键作用，其总部或在北美拥有重要业务。该地区拥有完善而强大的生物医学研究和开发生态系统。它拥有世界一流的大学、研究机构和致力于推进 mRNA 技术的高技能劳动力。北美为 mRNA 研发吸引了大量投资和资金。公共和私人资助机构、创投家和政府措施支持了基于 mRNA 的疗法和疫苗的发展。

目录

第 1 章：产品概述

  • 市场定义
  • 市场范围
    • 涵盖的市场
    • 考虑学习的年份
    • 主要市场区隔

第 2 章：研究方法

  • 研究目的
  • 基线方法
  • 主要产业伙伴
  • 主要协会和二手资料来源
  • 预测方法
  • 数据三角测量与验证
  • 假设和限制

第 3 章：执行摘要

  • 市场概况
  • 主要市场细分概述
  • 主要市场参与者概述
  • 重点地区/国家概况
  • 市场驱动因素、挑战、趋势概述

第 4 章：客户之声

第 5 章：全球 mRNA 平台市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依适应症（自体免疫疾病、癌症、传染病、罕见疾病、呼吸系统疾病）
    • 依可用性分类（预防性疫苗、治疗性药物、治疗性疫苗）
    • 依 mRNA 类型（核苷修饰 mRNA 、自扩增 mRNA 、未修饰 mRNA ）
    • 按最终用户（医院和诊所、製药公司、研究组织）
    • 按地区
    • 按公司划分 (2022)
  • 市场地图

第 6 章：亚太地区 mRNA 平台市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按指示
    • 按可用性
    • 依 mRNA 类型
    • 按最终用户
    • 按国家/地区
  • 亚太地区：国家分析
    • 中国mRNA平台
    • 印度 mRNA 平台
    • 澳洲 mRNA 平台
    • 日本mRNA平台
    • 韩国 mRNA 平台

第 7 章：欧洲 mRNA 平台市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按指示
    • 按可用性
    • 依 mRNA 类型
    • 按最终用户
    • 按国家/地区
  • 欧洲：国家分析
    • 法国
    • 德国
    • 西班牙
    • 义大利
    • 英国

第 8 章：北美 mRNA 平台市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按指示
    • 按可用性
    • 依 mRNA 类型
    • 按最终用户
    • 按国家/地区
  • 北美：国家分析
    • 美国
    • 墨西哥
    • 加拿大

第 9 章：南美洲 mRNA 平台市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按指示
    • 按可用性
    • 依 mRNA 类型
    • 按最终用户
    • 按国家/地区
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 10 章：中东和非洲 mRNA 平台市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按指示
    • 按可用性
    • 依 mRNA 类型
    • 按最终用户
    • 按国家/地区
  • MEA：国家分析
    • 南非 mRNA 平台
    • 沙乌地阿拉伯 mRNA 平台
    • 阿联酋 mRNA 平台

第 11 章：市场动态

  • 司机
  • 挑战

第 12 章：市场趋势与发展

  • 最近的发展
  • 产品发布
  • 併购

第 13 章：全球 mRNA 平台市场：SWOT 分析

第 14 章：波特的五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 客户的力量
  • 替代产品的威胁

第 15 章：大环境分析

第16章：竞争格局

  • 安进公司阿斯特捷利康公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 阿苏拉根公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 康泰伦特製药解决方案
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • Arcturus 治疗公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 生技公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • CRISPR 治疗公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • AKESOgen 公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 基克克有限公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 口音治疗公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • Accanis Biotech F&E GmbH & Co KG
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis

第 17 章：策略建议

第 18 章：关于我们与免责声明

简介目录
Product Code: 17266

Global mRNA Platform Market is anticipated to witness an impressive growth in the forecast period. The mRNA (messenger RNA) platform is a cutting-edge technology in biotechnology and medicine that uses synthetic RNA molecules to convey genetic information and instructions to cells, allowing them to produce specific proteins. This technology has gained significant attention and success, particularly in vaccine development and the treatment of various diseases. mRNA is a type of genetic material that normally carries instructions from DNA (the genetic code) to the cell's protein-making machinery (ribosomes). It serves as a temporary copy of a gene's instructions. In the mRNA platform, synthetic or modified mRNA molecules are designed to carry specific genetic instructions for producing a particular protein. Scientists can design and synthesize mRNA sequences with precise genetic information. This information can be customized for various purposes, such as producing therapeutic proteins or instructing the immune system to generate an immune response. In vaccine development, the mRNA platform is used to create mRNA vaccines. These vaccines contain mRNA molecules that encode a portion of the target pathogen, such as a viral protein or a unique antigen.

Beyond vaccines, the mRNA platform is used for therapeutic purposes. Researchers are exploring mRNA-based therapies for a wide range of conditions, including cancer, genetic disorders, autoimmune diseases, and allergies. In cancer immunotherapy, for example, mRNA is designed to instruct immune cells to target and attack cancer cells, harnessing the body's immune system to fight the disease. The COVID-19 pandemic accelerated the adoption of mRNA technology for vaccine development. The success of mRNA vaccines for COVID-19 generated enormous interest and investment in this technology, highlighting its potential in responding to emerging infectious diseases. mRNA technology's versatility allows for the development of vaccines and therapies for a wide range of diseases, including infectious diseases, cancer, genetic disorders, and autoimmune conditions. This adaptability makes it an attractive platform for addressing various medical challenges.

Key Market Drivers

Technological Advancements

Lipid Nanoparticle (LNP) Delivery Systems are crucial for delivering mRNA to cells efficiently. Advances in LNP design and formulation have improved the stability, delivery, and efficacy of mRNA vaccines and therapies. These advancements have played a pivotal role in the success of COVID-19 mRNA vaccines. Researchers have developed modified mRNA sequences with enhanced stability and reduced immunogenicity. This has extended the shelf life of mRNA vaccines and made them more suitable for distribution and storage. Codon optimization involves modifying the genetic code to improve protein expression. Researchers have been fine-tuning codon usage to enhance protein production, which is particularly important for therapeutic applications. Advances in synthetic biology techniques, such as CRISPR-Cas9, have facilitated the precise editing and manipulation of mRNA sequences. This technology has opened new possibilities for mRNA-based therapies targeting genetic diseases. Scalable and cost-effective manufacturing processes have been developed to meet the high demand for mRNA-based vaccines and therapies. These improvements in manufacturing have enabled rapid production during public health emergencies. Researchers have made progress in increasing the stability of mRNA vaccines at various temperature ranges, reducing the need for ultra-low-temperature storage and distribution. Next-Generation Sequencing (NGS) has enabled researchers to analyze mRNA sequences rapidly and accurately, facilitating the design of mRNA-based therapies tailored to specific targets.

Cap analogues are added to the beginning of mRNA sequences to mimic natural mRNA. This improves the translational efficiency of synthetic mRNA and increases its similarity to endogenous mRNA. Cell-free systems for mRNA production have been developed, allowing for more efficient and scalable synthesis of mRNA molecules for research and therapeutic purposes. Advancements in mRNA technology have enabled the development of personalized medicine approaches, where therapies are tailored to an individual's genetic profile. Adjuvants are substances added to vaccines to enhance the immune response. Research has focused on developing novel adjuvants specifically designed for mRNA-based vaccines. Innovations in intracellular delivery methods, such as electroporation and microneedle patches, have improved the efficient uptake of mRNA into target cells. Extensive research into mRNA formulation and stability has improved the ability to store and transport mRNA vaccines and therapies under various conditions. This factor will help in the development of the Global mRNA Platform Market.

Emerging Applications

One of the most promising emerging applications is cancer immunotherapy. Researchers are developing mRNA-based cancer vaccines and therapies that stimulate the patient's immune system to target and destroy cancer cells. This approach offers a personalized and potentially more effective treatment for various types of cancer. While mRNA vaccines have already demonstrated their effectiveness against infectious diseases like COVID-19, ongoing research aims to develop mRNA-based vaccines for other infectious diseases, such as influenza, HIV, Zika virus, and respiratory syncytial virus (RSV). The adaptability of mRNA technology makes it well-suited for responding to emerging pathogens. mRNA technology is being explored for the treatment of rare genetic disorders caused by specific mutations. By delivering modified mRNA to correct genetic defects, researchers aim to provide targeted and personalized therapies for patients with conditions like cystic fibrosis and certain inherited metabolic disorders. mRNA technology has potential applications in regenerative medicine by guiding the differentiation of stem cells into specific cell types for tissue repair and replacement. This could be particularly valuable for treating degenerative diseases and injuries. mRNA can be used to deliver gene-editing tools like CRISPR-Cas9 to target and modify specific genes. This technology holds promise for treating genetic diseases and correcting genetic mutations. Researchers are exploring mRNA to replace or supplement deficient proteins in patients with genetic or acquired protein deficiencies. This approach can be used to treat conditions like hemophilia and certain enzyme deficiencies.

mRNA technology is being investigated for the development of therapies for autoimmune diseases. By modulating the immune response, mRNA-based treatments may help regulate and control autoimmune conditions. mRNA vaccines can be customized to deliver allergen-specific immunotherapy for allergies. This approach offers the potential for more precise and effective allergy treatments. The ability to customize mRNA-based therapies based on an individual's genetic profile is a significant driver in personalized medicine. Tailoring treatments to a patient's unique genetic makeup can improve treatment outcomes. Beyond healthcare, mRNA technology has applications in biotechnology, including the production of recombinant proteins and enzymes. It also holds potential for use in other fields, such as agriculture and industrial biotechnology. This factor will pace up the demand of the Global mRNA Platform Market.

Growth in Pandemic Response and Vaccines

mRNA technology allowed for the rapid development of COVID-19 vaccines. Within a remarkably short timeframe, companies like Pfizer-BioNTech and Moderna developed, tested, and received emergency use authorization for mRNA-based COVID-19 vaccines. This speed of development was crucial in controlling the pandemic. mRNA vaccines have demonstrated high levels of efficacy against COVID-19, contributing to their rapid adoption and widespread use. The effectiveness of these vaccines in preventing severe illness and transmission has been a strong driver of demand. mRNA technology is well-suited to adapt to new virus variants. The flexibility of mRNA allows for the quick modification of vaccine candidates to address emerging variants of the virus, addressing concerns about vaccine effectiveness in the face of viral mutations. The scalability and rapid production capabilities of mRNA vaccines have supported global vaccination efforts. Governments, international organizations, and healthcare systems have sought to secure mRNA vaccines to protect their populations, driving demand for increased production.

The pandemic highlighted the importance of being prepared for emerging infectious diseases. Governments and organizations worldwide have recognized the potential of mRNA technology to respond quickly to future pandemics and have invested in building infrastructure and capabilities. The success of mRNA-based COVID-19 vaccines attracted substantial investment and funding from both the public and private sectors. This financial support has accelerated research and development efforts and expanded the mRNA platform's applications. Regulatory agencies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), collaborated closely with mRNA technology developers to expedite the regulatory approval process during public health emergencies. The effectiveness and safety of mRNA COVID-19 vaccines have contributed to public confidence in this technology. As a result, there has been increased acceptance of mRNA-based vaccines and therapies. The success of mRNA vaccines has spurred further research and development in the field. Researchers and companies are exploring the potential of mRNA technology for a wide range of applications, including vaccines and therapies for other infectious diseases. The global response to the pandemic has involved collaboration between countries, pharmaceutical companies, and research institutions. This collaboration has accelerated the sharing of knowledge and expertise in mRNA technology. This factor will accelerate the demand of the Global mRNA Platform Market.

Key Market Challenges

Vaccine Hesitancy and Misinformation

Vaccine hesitancy, which refers to the reluctance or refusal to get vaccinated, can slow down the adoption of mRNA vaccines. This can impede efforts to achieve herd immunity and control the spread of infectious diseases. Misinformation, often spread through social media and other channels, can lead to misconceptions and false beliefs about mRNA vaccines. This can include concerns about vaccine safety, efficacy, and long-term effects. Misinformation can undermine public confidence in vaccines and deter individuals from getting vaccinated. Lower vaccine coverage due to hesitancy and misinformation can lead to ongoing outbreaks of preventable diseases, including potentially deadly infectious diseases like COVID-19. These outbreaks can strain healthcare systems, result in increased morbidity and mortality, and have economic and societal consequences. High levels of vaccine hesitancy can hinder efforts to achieve herd immunity, which is essential for protecting vulnerable populations who cannot receive vaccines due to medical reasons. Herd immunity is crucial for controlling the spread of contagious diseases within communities. Misinformation and hesitancy can disrupt vaccination campaigns and lead to lower vaccine uptake rates, particularly during public health emergencies like pandemics. Widespread vaccine hesitancy and the propagation of vaccine misinformation can erode public trust in public health institutions, healthcare providers, and government recommendations. This erosion of trust can extend to other public health measures, making it more challenging to implement effective disease control strategies.

Variants and Adaptability

Many infectious pathogens, particularly viruses, can undergo genetic mutations that result in the emergence of new variants or strains. These variants can have different properties, including increased transmissibility and resistance to immunity. Variants can pose a threat to public health by potentially leading to more severe disease or reduced vaccine effectiveness. The effectiveness of vaccines, including mRNA vaccines, can vary against different variants. Some variants may partially evade the immune response induced by existing vaccines. This challenges the ability of vaccines to provide broad and long-lasting protection against evolving pathogens. To maintain vaccine effectiveness, researchers and manufacturers need to adapt mRNA vaccines quickly to address emerging variants. This may involve modifying the mRNA sequence to encode the antigen(s) of the new variant. Rapid adaptation is critical during pandemics and outbreaks to ensure that vaccines remain effective. Regulatory agencies may need to provide streamlined approval processes for variant-adapted vaccines to expedite their availability during public health emergencies. Developing and gaining regulatory approval for variant-specific vaccines can be resource-intensive and time-consuming. Adapting mRNA vaccines to address new variants may require adjustments in the manufacturing process. Scaling up production to meet global demand for updated vaccines can be challenging.

Key Market Trends

Personalized Medicine

Advances in genomics and genetic testing have made it increasingly feasible to analyze an individual's genetic information quickly and affordably. This genetic profiling allows healthcare providers to identify genetic variations that may impact disease susceptibility and treatment responses. mRNA technology enables the development of targeted therapies that can be customized based on a patient's genetic profile. By designing mRNA sequences to address specific genetic variations or disease markers, researchers can create personalized treatments. In the context of cancer, personalized medicine was a notable application. Researchers were exploring mRNA-based cancer vaccines and therapies that target individualized tumor antigens. These therapies aim to harness the patient's immune system to target and destroy cancer cells specifically. Personalized mRNA therapies were being developed to address rare genetic diseases caused by specific mutations. By tailoring mRNA sequences to correct or compensate for these mutations, researchers were working to provide individualized treatments. mRNA vaccines can be customized to deliver allergen-specific immunotherapy for allergies. This approach offers the potential for more precise and effective allergy treatments tailored to each patient's allergens. mRNA technology allows for the monitoring of a patient's response to treatment by analyzing changes in gene expression. This information can be used to adjust and personalize treatment plans. Integrating pharmacogenomic data with mRNA-based therapies can help determine the most suitable medications and dosages for individual patients, reducing adverse effects and optimizing treatment outcomes.

Segmental Insights

Indication Insights

In 2022, the Global mRNA Platform Market largest share was held by Autoimmune Diseases segment and is predicted to continue expanding over the coming years. Autoimmune diseases represent a significant medical challenge due to their complex and often poorly understood nature. Many autoimmune diseases have limited treatment options, and mRNA technology holds promise for developing innovative therapies to address unmet medical needs in this segment. mRNA technology can be used to modulate the immune system, making it an attractive approach for treating autoimmune diseases. By designing mRNA sequences to target specific immune responses, researchers can potentially suppress or regulate the immune system's harmful activities in autoimmune conditions. Autoimmune diseases often have variable manifestations and responses to treatment among patients. mRNA-based therapies can be customized to target specific autoimmune pathways or antigens, allowing for a personalized approach to treatment.

Usability Insights

In 2022, the Global mRNA Platform Market largest share was held by Therapeutic Vaccines segment and is predicted to continue expanding over the coming years. The COVID-19 pandemic had a significant impact on the mRNA platform market. mRNA technology emerged as a highly effective and rapid response to develop vaccines against the SARS-CoV-2 virus. The success of mRNA-based COVID-19 vaccines, such as those developed by Pfizer-BioNTech and Moderna, generated immense interest and investment in this segment. mRNA technology has demonstrated its versatility in the development of therapeutic vaccines for various diseases beyond infectious diseases. This includes cancer vaccines, where mRNA-based therapies aim to stimulate the immune system to target and destroy cancer cells, as well as vaccines for other diseases like influenza, Zika, and HIV. mRNA vaccines and therapeutic vaccines can be developed more rapidly than traditional vaccine platforms. This speed is especially valuable in responding to emerging infectious diseases and rapidly evolving pathogens.

mRNA Type Insights

In 2022, the Global mRNA Platform Market largest share was held by Self-Amplifying mRNA segment and is predicted to continue expanding over the coming years. Self-amplifying mRNA (saRNA) technology is designed to produce higher levels of protein expression compared to conventional mRNA. This enhanced protein production capability can make saRNA particularly attractive for vaccine development and therapies targeting diseases that require a robust immune response. Self-amplifying mRNA can be engineered to carry genetic information for a wide range of antigens or therapeutic proteins. This versatility makes it a valuable tool for developing vaccines and therapies against various diseases, including infectious diseases and cancer. The development of advanced lipid nanoparticles (LNPs) for the delivery of self-amplifying mRNA has improved the stability and delivery efficiency of saRNA-based vaccines and therapies, further contributing to their market share.

End-User Insights

In 2022, the Global mRNA Platform Market largest share was held by Pharmaceutical Companies segment in the forecast period and is predicted to continue expanding over the coming years. Pharmaceutical companies have a long history of conducting extensive research and development (R&D) in the field of drug discovery and development. They possess the scientific expertise, infrastructure, and financial resources required to advance mRNA-based therapies and vaccines. mRNA technology has shown immense promise for developing vaccines and therapeutics for a wide range of diseases, including infectious diseases, cancer, and rare genetic disorders. Pharmaceutical companies have the experience and capabilities to bring these products from the research stage to clinical trials and ultimately to commercialization. Running clinical trials is a critical part of drug development. Pharmaceutical companies have the capacity to conduct large-scale clinical trials, which are necessary for gaining regulatory approvals and demonstrating the safety and efficacy of mRNA-based products.

Regional Insights

The North America region dominates the Global mRNA Platform Market in 2022. North America is home to some of the world's largest and most influential biotechnology and pharmaceutical companies, many of which have invested heavily in mRNA technology. Companies like Pfizer, Moderna, and BioNTech, which played pivotal roles in the development and commercialization of mRNA-based COVID-19 vaccines, are headquartered, or have a significant presence in North America. The region has a well-established and robust ecosystem for biomedical research and development. It boasts world-class universities, research institutions, and a highly skilled workforce dedicated to advancing mRNA technology. North America has attracted substantial investment and funding for mRNA research and development. Public and private funding agencies, venture capitalists, and government initiatives have supported the growth of mRNA-based therapies and vaccines.

Key Market Players

  • AstraZeneca PLC
  • Asuragen, Inc.
  • Catalent Pharma Solutions
  • Arcturus Therapeutics, Inc.
  • BioNTech AG
  • CRISPR Therapeutics Inc.
  • AKESOgen, Inc.
  • baseclick GmbH
  • Accent Therapeutics Inc.
  • Accanis Biotech F&E GmbH & Co KG

Report Scope:

In this report, the Global mRNA Platform Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

mRNA Platform Market, By Indication:

  • Autoimmune Diseases
  • Cancer
  • Personalized Treatment
  • Single Cancer Focussed
  • Infectious Diseases
  • Rare Diseases
  • Respiratory Diseases

mRNA Platform Market, By Usability:

  • Prophylactic Vaccines
  • Therapeutic Drugs
  • Therapeutic Vaccines

mRNA Platform Market, By mRNA Type:

  • Nucleoside-Modified mRNA
  • Self-Amplifying mRNA
  • Unmodified mRNA

mRNA Platform Market, By End-User:

  • Hospitals & Clinics
  • Pharmaceutical Companies
  • Research Organization

Global mRNA Platform Market, By region:

  • North America
  • United States
  • Canada
  • Mexico
  • Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global mRNA Platform Market.

Available Customizations:

  • Global mRNA Platform Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global mRNA Platform Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Indication (Autoimmune Diseases, Cancer, Infectious Diseases, Rare Diseases, Respiratory Diseases)
    • 5.2.2. By Usability (Prophylactic Vaccines, Therapeutic Drugs, Therapeutic Vaccines)
    • 5.2.3. By mRNA Type (Nucleoside-Modified mRNA , Self-Amplifying mRNA , Unmodified mRNA )
    • 5.2.4. By End User (Hospitals & Clinics, Pharmaceutical Companies, Research Organization)
    • 5.2.5. By Region
    • 5.2.6. By Company (2022)
  • 5.3. Market Map

6. Asia Pacific mRNA Platform Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Indication
    • 6.2.2. By Usability
    • 6.2.3. By mRNA Type
    • 6.2.4. By End User
    • 6.2.5. By Country
  • 6.3. Asia Pacific: Country Analysis
    • 6.3.1. China mRNA Platform Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Indication
        • 6.3.1.2.2. By Usability
        • 6.3.1.2.3. By mRNA Type
        • 6.3.1.2.4. By End User
    • 6.3.2. India mRNA Platform Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Indication
        • 6.3.2.2.2. By Usability
        • 6.3.2.2.3. By mRNA Type
        • 6.3.2.2.4. By End User
    • 6.3.3. Australia mRNA Platform Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Indication
        • 6.3.3.2.2. By Usability
        • 6.3.3.2.3. By mRNA Type
        • 6.3.3.2.4. By End User
    • 6.3.4. Japan mRNA Platform Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Indication
        • 6.3.4.2.2. By Usability
        • 6.3.4.2.3. By mRNA Type
        • 6.3.4.2.4. By End User
    • 6.3.5. South Korea mRNA Platform Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Indication
        • 6.3.5.2.2. By Usability
        • 6.3.5.2.3. By mRNA Type
        • 6.3.5.2.4. By End User

7. Europe mRNA Platform Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Indication
    • 7.2.2. By Usability
    • 7.2.3. By mRNA Type
    • 7.2.4. By End User
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France mRNA Platform Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Indication
        • 7.3.1.2.2. By Usability
        • 7.3.1.2.3. By mRNA Type
        • 7.3.1.2.4. By End User
    • 7.3.2. Germany mRNA Platform Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Indication
        • 7.3.2.2.2. By Usability
        • 7.3.2.2.3. By mRNA Type
        • 7.3.2.2.4. By End User
    • 7.3.3. Spain mRNA Platform Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Indication
        • 7.3.3.2.2. By Usability
        • 7.3.3.2.3. By mRNA Type
        • 7.3.3.2.4. By End User
    • 7.3.4. Italy mRNA Platform Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Indication
        • 7.3.4.2.2. By Usability
        • 7.3.4.2.3. By mRNA Type
        • 7.3.4.2.4. By End User
    • 7.3.5. United Kingdom mRNA Platform Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Indication
        • 7.3.5.2.2. By Usability
        • 7.3.5.2.3. By mRNA Type
        • 7.3.5.2.4. By End User

8. North America mRNA Platform Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Indication
    • 8.2.2. By Usability
    • 8.2.3. By mRNA Type
    • 8.2.4. By End User
    • 8.2.5. By Country
  • 8.3. North America: Country Analysis
    • 8.3.1. United States mRNA Platform Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Indication
        • 8.3.1.2.2. By Usability
        • 8.3.1.2.3. By mRNA Type
        • 8.3.1.2.4. By End User
    • 8.3.2. Mexico mRNA Platform Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Indication
        • 8.3.2.2.2. By Usability
        • 8.3.2.2.3. By mRNA Type
        • 8.3.2.2.4. By End User
    • 8.3.3. Canada mRNA Platform Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Indication
        • 8.3.3.2.2. By Usability
        • 8.3.3.2.3. By mRNA Type
        • 8.3.3.2.4. By End User

9. South America mRNA Platform Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Indication
    • 9.2.2. By Usability
    • 9.2.3. By mRNA Type
    • 9.2.4. By End User
    • 9.2.5. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil mRNA Platform Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Indication
        • 9.3.1.2.2. By Usability
        • 9.3.1.2.3. By mRNA Type
        • 9.3.1.2.4. By End User
    • 9.3.2. Argentina mRNA Platform Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Indication
        • 9.3.2.2.2. By Usability
        • 9.3.2.2.3. By mRNA Type
        • 9.3.2.2.4. By End User
    • 9.3.3. Colombia mRNA Platform Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Indication
        • 9.3.3.2.2. By Usability
        • 9.3.3.2.3. By mRNA Type
        • 9.3.3.2.4. By End User

10. Middle East and Africa mRNA Platform Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Indication
    • 10.2.2. By Usability
    • 10.2.3. By mRNA Type
    • 10.2.4. By End User
    • 10.2.5. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa mRNA Platform Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Indication
        • 10.3.1.2.2. By Usability
        • 10.3.1.2.3. By mRNA Type
        • 10.3.1.2.4. By End User
    • 10.3.2. Saudi Arabia mRNA Platform Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Indication
        • 10.3.2.2.2. By Usability
        • 10.3.2.2.3. By mRNA Type
        • 10.3.2.2.4. By End User
    • 10.3.3. UAE mRNA Platform Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Indication
        • 10.3.3.2.2. By Usability
        • 10.3.3.2.3. By mRNA Type
        • 10.3.3.2.4. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global mRNA Platform Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

  • 16.1. Amgen Inc. AstraZeneca PLC
    • 16.1.1. Business Overview
    • 16.1.2. Company Snapshot
    • 16.1.3. Products & Services
    • 16.1.4. Financials (In case of listed companies)
    • 16.1.5. Recent Developments
    • 16.1.6. SWOT Analysis
  • 16.2. Asuragen, Inc.
    • 16.2.1. Business Overview
    • 16.2.2. Company Snapshot
    • 16.2.3. Products & Services
    • 16.2.4. Financials (In case of listed companies)
    • 16.2.5. Recent Developments
    • 16.2.6. SWOT Analysis
  • 16.3. Catalent Pharma Solutions
    • 16.3.1. Business Overview
    • 16.3.2. Company Snapshot
    • 16.3.3. Products & Services
    • 16.3.4. Financials (In case of listed companies)
    • 16.3.5. Recent Developments
    • 16.3.6. SWOT Analysis
  • 16.4. Arcturus Therapeutics, Inc.
    • 16.4.1. Business Overview
    • 16.4.2. Company Snapshot
    • 16.4.3. Products & Services
    • 16.4.4. Financials (In case of listed companies)
    • 16.4.5. Recent Developments
    • 16.4.6. SWOT Analysis
  • 16.5. BioNTech AG
    • 16.5.1. Business Overview
    • 16.5.2. Company Snapshot
    • 16.5.3. Products & Services
    • 16.5.4. Financials (In case of listed companies)
    • 16.5.5. Recent Developments
    • 16.5.6. SWOT Analysis
  • 16.6. CRISPR Therapeutics Inc.
    • 16.6.1. Business Overview
    • 16.6.2. Company Snapshot
    • 16.6.3. Products & Services
    • 16.6.4. Financials (In case of listed companies)
    • 16.6.5. Recent Developments
    • 16.6.6. SWOT Analysis
  • 16.7. AKESOgen, Inc.
    • 16.7.1. Business Overview
    • 16.7.2. Company Snapshot
    • 16.7.3. Products & Services
    • 16.7.4. Financials (In case of listed companies)
    • 16.7.5. Recent Developments
    • 16.7.6. SWOT Analysis
  • 16.8. Baseclick GmbH
    • 16.8.1. Business Overview
    • 16.8.2. Company Snapshot
    • 16.8.3. Products & Services
    • 16.8.4. Financials (In case of listed companies)
    • 16.8.5. Recent Developments
    • 16.8.6. SWOT Analysis
  • 16.9. Accent Therapeutics Inc.
    • 16.9.1. Business Overview
    • 16.9.2. Company Snapshot
    • 16.9.3. Products & Services
    • 16.9.4. Financials (In case of listed companies)
    • 16.9.5. Recent Developments
    • 16.9.6. SWOT Analysis
  • 16.10. Accanis Biotech F&E GmbH & Co KG
    • 16.10.1. Business Overview
    • 16.10.2. Company Snapshot
    • 16.10.3. Products & Services
    • 16.10.4. Financials (In case of listed companies)
    • 16.10.5. Recent Developments
    • 16.10.6. SWOT Analysis

17. Strategic Recommendations

18. About Us & Disclaimer